{"editorial":{"content_id":"968f6871-5e07-4e93-b93a-9ae0a7450da4","slug":"anvisa-eli-lilly-tirzepatida-20261111-36e2b5","content_type":"news","title":"Anvisa否决Eli Lilly中国工厂tirzepatida良好生产规范认证申请","summary":"巴西国家卫生监督局以文件不足为由，否决了Eli Lilly巴西子公司为中国江苏Taixing Syntheall Pharmaceutical工厂申请的良好生产规范认证。","body":"巴西国家卫生监督局（Anvisa）否决了Eli Lilly do Brasil为Taixing Syntheall Pharmaceutical中国工厂申请的良好生产规范（CBPF）认证。该工厂位于中国江苏省，被指定用于tirzepatida（Mounjaro的活性成分）的化学合成。\n\n这一决定载于11月5日签署、四天后在联邦官方公报（DOU）上发布的第4.357号决议。申请通过国际制造商优化认证程序审理。\n\n据决议附件，否决原因是缺乏能够证明该设施符合良好生产规范认证所需技术要求的文件。\n\n据CNBC旗下Times Brasil报道，此次否决涉及中国工厂合规性的文件证明，本身并不决定暂停销售或召回批次。DOU发布也未说明Eli Lilly是否打算提交新文件或对决定提出上诉。\n\n该决定公布之际正值关于tirzepatida配制的讨论。Eli Lilly在公开信中声称，自己是唯一被授权合法大规模生产该活性成分药物的公司。10月，该实验室获得初步禁令，暂停了圣保罗州Urupês市政府分发该药物配制版本；但11月初，圣保罗州法院（TJSP）授权恢复该服务。","why_it_matters":null,"cbi_observation":null,"direction_tag":"双边","primary_category":"科技平台","secondary_topics":["合规","法律","企业动态","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-11T23:03:31.511Z","display_date":"2026-11-11","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/anvisa-indefere-certificacao-de-fabrica-de-tirzepatida/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-eli-lilly-tirzepatida-20261111-36e2b5","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-eli-lilly-tirzepatida-20261111-36e2b5","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-eli-lilly-tirzepatida-20261111-36e2b5?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-eli-lilly-tirzepatida-20261111-36e2b5?view=json","last_updated":"2026-11-11T23:03:55.221Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}